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Pancreatic cysts are challenging lesions to diagnose and to treat. Determining which of the ﬁve most common diagnoses—
pancreatic pseudocyst, serous cystic neoplasm (SCN), solid pseudopapillary neoplasm (SPN), mucinous cystic neoplasm (MCN),
andintraductalmucinouspapillaryneoplasm(IPMN)—islikelythecorrectonerequiresthecarefulintegrationofmanyhistorical,
radiographic, laboratory, and other factors, and management is markedly diﬀerent depending on the type of cystic lesion of the
pancreas. Pseudocysts are generally distinguishable based on historical, clinical and radiographic characteristics, and among the
others, the most important diﬀerentiation is between the mucin-producing MCN and IPMN (high risk for cancer) versus the
serous SCN and SPN (low risk for cancer). EUS with FNA and cyst-ﬂuid analysis will continue to play an important role in
diagnosis. Among mucinous lesions, those that require treatment (resection currently) are any MCN, any MD IPMN, and BD
IPMN larger than 3cm, symptomatic, or with an associated mass, with the understanding that SCN or pseudocysts may be
removed inadvertently due to diagnostic inaccuracy, and that a certain proportion of SPN will indeed be malignant at the time of
removal. The role of ethanol ablation is under investigation as an alternative to resection in selected patients.
1.Introduction
Pancreatic cysts are common in the general population.
The reported incidence of asymptomatic cysts varies widely,
largely due to diﬀerences in study design, ranging between
0.7% and 24.3% [1–4] .T h el o w e s te s t i m a t ec o m e sf r o ma
study employing both single- and multidetector CT scanners
and relying on original dictated reports as opposed to
rereview of images [1], while the highest estimates come
from autopsy studies and studies including both symp-
tomatic and asymptomatic patients [3, 4]. The incidence
of truly asymptomatic cysts in the general population is
approximately 2.6% [2]. In large series of pancreatic cysts
[5], most (71%) cysts are largely asymptomatic and range
from benign to premalignant to malignant cysts. The most
useful ﬁrst dichotomy in the long diﬀerential diagnosis
(Table 1) of pancreatic cysts is their classiﬁcation as either
neoplastic or nonneoplastic. Nonneoplastic cysts include
pseudocysts, retention cysts, and duplication cysts, whereas
neoplastic cysts are further broadly classiﬁed as mucinous
and nonmucinous cysts. The more common—and more
commonly malignant—mucinous neoplasms include pri-
marily intraductal papillary mucinous neoplasm (IMPN)
andmucinouscysticneoplasms(MCN),whilenonmucinous
neoplastic cysts include primarily serous cystic neoplasm
(SCN), solid pseudopapillary neoplasm (SPN), and usually
solid neoplasms with degenerative cystic changes [6, 7].
Whereas most serous cystic neoplasms are not malignant,
intraductal papillary mucinous neoplasms and mucinous
cystic neoplasms can harbor an associated invasive carci-
noma and should be treated as having malignant potential.
Diﬀerentiating among these cysts is challenging, and a
variety of modalities—including imaging, cytology, and cyst
ﬂuid analysis—are useful. The management of pancreatic2 Diagnostic and Therapeutic Endoscopy
Table 1: Diﬀerential diagnosis of pancreatic cysts.
Nonneoplastic lesions Neoplastic lesions
IPMN
Pseudocysts MCN
SCN
Syndromes causing multiple
cysts SPN
(i) Autosomal dominant
polycystic disease
(ii) Cystic ﬁbrosis
Infectious cysts Cystic variants of solid tumors
(i) Hydatid cysts (i) Cystic teratoma
(ii) Abscess (ii) Cystic ductal
adenocarcinoma
(iii) Cystic neuroendocrine
tumor
(iv) Cystic acinar cell carcinoma
Lymphoepithelial cysts (v) Cystic metastases
Congenital epithelial cysts
Duplication cysts
Retention cysts
cystic lesions continues to evolve. The purpose of this paper
is to review the current approaches to the diagnosis and
management of pancreatic cystic lesions.
2.Nonneoplastic PancreaticCysts
Pseudocysts are deﬁned as a collection of pancreatic ﬂuid
enclosed by a wall of nonepithelialized granulation tissue
(Figure 5: Pancreatic pseudocyst). They are caused by the
abnormal release of pancreatic enzymes into the tissues
that might result from pancreatic duct disruption related
to pancreatitis or trauma. In the absence of a history of
pancreatitis or trauma, this diagnosis should be considered
very unlikely.
Retention cysts, duplication cysts, and other rare non-
neoplastic cysts of the pancreas (Table 1)c a nb ed i ﬃcult to
distinguish from more common lesions, and therefore cli-
nical, laboratory, and radiographic characteristics guide the
decision to treat or to observe, as discussed below.
3.Neoplastic PancreaticCysts
Themostimportantdistinctionamongneoplasticcystsisthe
categorization of mucinous versus nonmucinous. The most
common nonmucinous neoplastic cysts are SCN and SPN,
while the most common mucinous lesions include IPMN
and MCN.
SCNs represent approximately 7%–36% of all cystic
neoplasms [5, 8, 9] and are present in middle-aged females,
evenly distributed throughout the pancreas, and character-
ized grosslyby amicrocysticappearanceand acentralstellate
scar that often corresponds radiographically with a pattern
of central sunburst calciﬁcation on CT imaging (Figure 6:
SCN). They grow slowly, and their potential for malignancy
is extremely low, but when these cysts are greater than 4cm
or causing symptoms, surgical resection is recommended
[10, 11].
Previously known by the eponymous terms Hamoudi
tumor or Franz tumor, SPNs are typically benign mixed
solid/cystic tumors that are associated with young age
(median 32–38 years) and female gender (84%–89%)
[12, 13]. Grossly, they are often ﬁlled with bloody or
necrotic debris and radiographically have a similarly mixed
solid/cystic appearance, with calciﬁcations commonly seen
(Figure 7:S P N )[ 14]. SPNs are now considered potentially
malignant, and 10% to 15% of patients have or ultimately
develop metastases [13, 15–17].
Cystic variants of solid tumors are some of the many rare
cystic lesions that may also be present in the pancreas. For
example, ductal adenocarcinoma, acinar adenocarcinoma,
and neuroendocrine tumors all may undergo cystic degener-
ationandmaypresentasprimarilycysticlesions(Table 1)[5,
7, 8, 18]. In a recent study of over 1,400 cystic lesions of the
pancreas, 7% were cystic pancreatic neuroendocrine tumors
and 14% were adenocarcinomas with cystic degeneration
[8].
Previously known as “mucin-producing tumor” and
“mucinous ductal ectasia,” IPMN is a grossly visible (typ-
ically ≥1.0cm) intraductal epithelial neoplasm composed
of mucin-producing cells. IPMNs may arise from either
the main pancreatic duct (MD IPMN), branch ducts (BD
IPMN), or both (Figures 2 and 3)[ 19, 20]. IPMN is most
common in elderly patients, males more than females, and
located in the head of the pancreas more often than the
tail.Themalignantpotentialisvariable,dependingpredomi-
nantlyonthelocationoftheIPMN:thepercentageofIPMNs
found after resection to harbor a malignancy (invasive
carcinoma or carcinoma in situ) ranges in various studies
from6%to46%forBDIPMNandfrom49%to92%forMD
IPMNs[5,8,21–26].IfcarcinomadevelopswithinanIPMN,
survival depends on the subtype: colloid adenocarcinomas
are associated with a more favorable survival than tubular
adenocarcinomas,whichareassociatedwitha5-yearsurvival
ratenotstatisticallydiﬀerentfromconventional,non-IPMN-
related pancreatic ductal adenocarcinoma [27, 28].
In contradistinction to IPMN, MCNs do not involve
the duct system and have an associated ovarian-type of
stroma. MCNs also have a strong female predominance and
are found almost exclusively in the body and tail of the
pancreas.MCNsaretypicallymacrocystic(>2cm),spheroid,
solitary, and associated with a normal pancreatic duct with
which there is no communication [7]( Figure 4:M C N ) .I na
recent, large, two-institution series, approximately 11% were
invasive [23].
4.DiagnosticModalities
The two noninvasive imaging modalities which have been
most frequently used to evaluate pancreatic cysts are com-
puted tomography (CT) and magnetic resonance imaging
(MRI). Pancreas-protocol CT scan (with the IV contrastDiagnostic and Therapeutic Endoscopy 3
Imaging ﬁndings
Questionable ﬁndings
Consider resection
Good operative risk Poor operative risk Surveillanceb
Consider ablationc
Pancreas-protocol CT
EUS/FNA ± ERCP
Suspicious ﬁndingsa (e.g.,
MD IPMN, size > 3cm,
mural nodules, septations)
Reassuring ﬁndings (e.g.,
very small, peripheral,
simple cysts)
Figure 1: Pancreatic cyst therapeutic algorithm. aAlso considered are nonimaging ﬁndings such as symptoms attributable to the cyst, rapid
growth, and young age. bSurveillance may be performed initially at close intervals (e.g., 3mo), and later spaced out to every 6, 12, or 24
months. cNB: cyst ablation is largely experimental and not appropriate for main-duct IPMNs. Abbreviations: see text.
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Figure 2: Main-duct intraductal papillary mucinous neoplasm. (a)
Typical CT (arrows) and (b) EUS (cross marks) appearance.
bolus timed for both arterial and venous phases and typically
with water as the oral contrast to minimize artifacts arising
from denser contrast media) has become the preferred mod-
ality to evaluate the pancreas due to its ease, relatively low
expense, and diagnostic accuracy [29–31]. However, some
authors have argued that MRI with magnetic resonance
cholangiopancreatography (MRCP) is the best noninvasive
method for identifying the presence or absence of commu-
nication between pancreatic cysts and the pancreatic ductal
system [32]. While MRI/MRCP has the clear advantage over
CT of not involving the use of ionizing radiation, it lacks the
(a)
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Figure 3: Branch-duct intraductal papillary mucinous neoplasm.
(a) CT and (b) EUS showing associated mass (cross marks).
ability to sample cyst ﬂuid for analysis, which, as discussed
below, can help distinguish between high-risk mucinous and
low-risk nonmucinous cysts.
Endoscopicretrogradecholangiopancreatography(ERCP)
has been useful in cases of IPMN especially when combined
with pancreatoscopy and/or intraductal ultra-sound. Hara et
al. [33] found that lesions protruding more than 4mm into
the pancreatic duct were malignant in 88% of cases. ERCP,
althoughmoreinvasivethanMRCP,isveryusefulindeﬁning
thecommunicationofthecystwiththemainpancreaticduct
and provides another method for tissue acquisition. Due to4 Diagnostic and Therapeutic Endoscopy
(a)
D1
(b)
Figure 4: Mucinous cystic neoplasm. (a) Typical CT and (b)
EUS appearance of a well-rounded hypodense and anechoic,
respectively, pancreatic cyst in the tail of the gland of a female
patient.
itsassociatedriskofpancreatitis,however,andtheimproving
qualityofMRCP,itsrolehasbecomelimitedinfavorofendo-
scopic ultrasound (EUS).
EUS with ﬁne-needle aspiration (FNA) has been exten-
sively studied in the detection, diagnosis, and treatment of
pancreatic cysts [34, 35]. The diagnostic accuracy of EUS
morphologyaloneiswidelyvariablewiththelargestprospec-
tive study reporting an accuracy of 50% for identiﬁca-
tion of macrocystic septations or adjacent mass [36]. FNA
increases the sensitivity of EUS by allowing for cyst ﬂuid
analysis and cytology to further diﬀerentiate mucinous cysts,
serous cysts, and pseudocysts [7]. Columnar epithelial cells
which stain for mucin are characteristic of MCN and
IPMN, whereas cuboidal cells which stain for glycogen are
associated with serous cystadenomas. A recent study by
Rogart et al. [37] showed that EUS with FNA and cyst
wall puncture (passing the needle repeatedly through the
far wall of the cyst to obtain wall epithelium for cytology
after simple aspiration of cyst ﬂuid) increased the cytologic
yield by 37% compared to simple FNA with ﬂuid analysis
alone. The increased diagnostic capabilities of EUS/FNA
compared with noninvasive modalities must be balanced,
however, with the associated risks, including pancreatitis and
hemorrhage [37]. In general EUS/FNA is associated with
a favorable risk/beneﬁt ratio, as evidenced by several large
studiesincludingseveralhundredpatientssuﬀeringnomajor
PP
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Figure 5: Pancreatic pseudocyst. (a) Typical appearance on CT,
showing a dominant pseudocyst with a smaller pseudocyst imping-
ing slightly on the air- and ﬂuid-ﬁlled duodenum. (b) Typical EUS
appearance of a pseudocyst, with debris.
complications [34, 35]. In addition to being used to evaluate
cystic lesions of the pancreas found by other modalities,
EUS/FNA is also potentially useful as a screening modality
in individuals deemed to have ≥10-fold increased risk of
harboringapancreaticcancer,suchasthosewith ≥3r elati v es
with pancreas cancer in the same lineage [38].
While imaging modalities provide morphologic charac-
teristics of the lesions, it is the ﬂuid analysis and tumor-
marker levels that ultimately classify a cyst as of high or
low risk for malignancy. Cyst ﬂuid amylase level is elevated
in pseudocysts and IPMNs. IPMNs have elevated amylase
levels because, by deﬁnition, they involve the pancreatic duct
system. By contrast, SCNs and MCNs, because they do not
communicate with the pancreatic duct system, typically have
lower amylase levels. Carcinoembryonic antigen (CEA) level
is the most studied and widely used tumor marker in dif-
ferentiating mucinous from nonmucinous lesions. Although
no cutoﬀ level is universally agreed upon, a cyst-ﬂuid CEA
level <30ng/mL has a sensitivity of 79% and speciﬁcity of
73% in diﬀerentiating nonmucinous from mucinous lesions
[39]. In the Cooperative Pancreatic Cyst Study, a higher cut-
oﬀ (192ng/mL) was found to be optimal, with a sensitivity
of 73%, a speciﬁcity of 84%, and an accuracy of 79%
for diagnosing nonmucinous from mucinous lesions [36].
Although CEA has been found to have the highest accuracy
among cyst ﬂuid analyses in distinguishing mucinous fromDiagnostic and Therapeutic Endoscopy 5
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Figure 6: Serous cystic neoplasm: (a) CT and (b) EUS images both
showing the central starburst calciﬁcation pattern characteristic of
serous cystic neoplasms.
nonmucinous cysts, other tumor markers have also been
predictive. For instance, in the same Cooperative Study, cyst
ﬂuid CA19-9 levels had a sensitivity of 68%, a speciﬁcity of
62%, and an accuracy of 66% (P = 0.004) with a cutoﬀ
value of 2900U/mL for diﬀerentiating nonmucinous from
mucinous lesions [36]; corresponding numbers for CA72-4
were 80%, 61%, and 72% (P = 0.001).
The demographic, historical, radiographic, gross, and
cyst ﬂuid analysis characteristics described above are sum-
marized in Table 2 and are electronically available in an
interactive, online pancreatic cyst worksheet available at
http://pathology.jhu.edu/pancreas/professionals/ipmn.php
[7].
4.1. Emerging Modalities. Loss-of-heterozygosity studies and
DNA mutational analysis of cyst ﬂuid have shown that the
presence of a point mutation in the KRAS gene is 96%
speciﬁc in detecting a mucinous neoplasm, and when there
is a KRAS gene point mutation coupled with allelic loss
at selected markers, there is a 96% speciﬁcity in detecting
malignancy (invasive versus in situ carcinoma not speciﬁed)
[41]. However, this study has been rightfully criticized for
harboring a selection bias resulting from the exclusion of
nonoperated patients from cyst ﬂuid DNA analysis [42].
Furthermore, there is poor correlation between cysts with
high CEA levels and those with KRAS point mutations and
(a)
(b)
Figure 7: Solid pseudopapillary neoplasm: (a) Typical CT and (b)
EUS appearance of solid and cystic components.
allelic loss. There are a number of other biomarkers that are
currently under evaluation to predict risk in pancreatic cysts
[43, 44].
Confocal laser endomicroscopy (CLE) [45] is an exciting
emerging diagnostic modality that employs a low-power
laser to illuminate tissue with subsequent detection light re-
ﬂected from the tissue through a small probe (pCLE) or
needle (nCLE). It is “confocal” because both illumination
and collection systems are aligned in the same focal plane
[45]. While largely still experimental, nCLE has been used
successfully in a porcine model to collect real-time, in vivo
pancreatic images at histologic resolutions and of acceptable
image quality [46].
5. Management
5.1. Nonneoplastic Cysts. Initially, the management of pseu-
docysts is conservative since as many as 60% may completely
resolve spontaneously within a year [47]. As such, surveil-
lance is the ﬁrst-line therapy for noninfected pancreatic
pseudocysts and may be done with US, CT, or MRI.
Pseudocysts that either cause severe symptoms or are large
and refractory to surveillance should be drained percu-
taneously, endoscopically, or surgically. The disadvantages
of percutaneous drainage include risk of infection, ﬁstula
formation,andalowrate(21%)ofresolution[48].Openand
laparoscopic internal surgical management—including in-
ternal and external drainage as well as resection—is eﬀective,
butisassociatedwith12%–35%complicationrate,including
hemorrhage, infection, and ﬁstulae, and a mortality rate6 Diagnostic and Therapeutic Endoscopy
Table 2: Distinguishing features of pancreatic cystic lesions∗.
Typical
characteristics IPMN MCN SCN PSEUDO SPN LEC cNET cPDAC
Age group Elderly Middle Middle-
elderly Any Young Elderly Middle-
Elderly Elderly
Gender >50% male 95% female >50% female >50% male 80%–90%
female 80% male 50% each >50% male
History Asx; pain;
± jaundice
Asx; Pain;
nausea Asx; VHL Pancreatitis Asx; pain;
nausea Asx Asx; Fxnl;
MEN
Asx; pain;
± jaundice
%o fa l l
cysts∗∗∗ 17%–40% 9%–28% 7%–36% 1%–19% 1%–13% <2% <8% 13%–16%
Location in
pancreas
Head in 70%;
multifocal
Body/Tail in
95% Anywhere Anywhere Anywhere Peripheral Anywhere Anywhere
Shape Ovoid Spheroid Ovoid Spheroid Ovoid Ovoid Spheroid Variable
Locularity Any Uni- or oligo- Oligo- or
multi- Uni- Oligo- or
Multi- Oligo- Uni- Any
Duct com-
munication Common No No Common No No No Some
Calciﬁcation No No Central
sunburst No Some No Some No
Cyst ﬂuid
appearance
Viscous, clear,
muc.
Viscous, clear,
muc.
Thin, clear,
nonmuc.
Opaque,
bloody/
necrotic
debris
Opaque,
bloody/
necrotic
debris
Nonmuc.,
crystalline
debris
Nonmuc. Thin
High
CEA/Mucin∗∗ ++−−−−−±
High Ca19-9 ±±−−−−−±
High amylase + −−+ −−−±
Epithelium Columnar,
papillary Columnar Cuboidal No epithelium
Poorly
cohesive cells
with nuclear
grooves
Squamoid Uniform Gland-
forming
Stroma Fibrotic Ovarian Fibrotic Fibrotic Sometimes
hyalinized Lymphoid Sometimes
hyalinized Fibrotic
Abbreviations:IPMN:intraductalpapillarymucinousneoplasm;MCN:mucinouscysticneoplasm;SC:serouscystadenoma;PSEUDO:pancreaticpseudocyst;
SPN:solid-pseudopapillaryneoplasm;LEC:lymphoepithelialcyst;cNET:cysticneuroendocrinetumor;cPDAC:pancreaticductaladenocarcinomawithcystic
degeneration; VHL: von Hippel-Lindau disease; muc.: mucinous; Nonmuc: nonmucinous; Asx: asymptomatic; Fxnl: functional.
∗∗∗Percentages references [8, 9, 22, 40].
∗∗May be positive in cases of luminal contamination of endoscopic needle aspirate.
NB: These data are derived generalizations of the literature, with the understanding that there is signiﬁcant overlap among cyst types and there are inherent
sampling errors associated with various tests; diagnostic and treatment decisions should not rely solely on the information presented in this paper.
∗Table modiﬁed from [7] by Cunningham et al. Intraductal papillary mucinous neoplasms are diﬀerentiated from other pancreatic cystic lesions. World J
GastrointestSurg2010;2(10):331–336.Anelectronicworksheetversionofthistableisavailableathttp://pathology.jhu.edu/pancreas/professionals/ipmn.php.
of 1% [49–51]. Endoscopic drainage has been reported to
achieve a similarly high success rate but with lower rates of
complications, including bleeding, infection, perforation,
andmildpancreatitis,whichisgenerallyself-limited[52,53].
Endoscopicdrainagehasthereforebecomethepreferredmo-
dality for draining cysts which have a mature wall and are
within1cmofthegastrointestinallumen.Inarecentlargere-
trospective study by Ahn et al. [54], single-step EUS-guided
transmural drainage and stent placement was eﬀective in
89% of patients with complete drainage, with an overall re-
currence rate of 12% and minor complications in 11% of
patients.
Unlike pancreatic pseudocysts, which are typically iden-
tiﬁable as such based on historical, clinical, laboratory, and
radiographic information, other nonneoplastic cysts such as
duplication cysts, retention cysts, congenital epithelial cysts,
andlymphoepithelialcystsarerarer,andnoteasilydiagnosed
preoperatively. As such, they are typically subjected to the
various diagnostic modalities described above in an eﬀort to
classify them correctly as low-risk versus high-risk cysts and
they are treated or surveilled accordingly.
5.2. Neoplastic Cysts
5.2.1.IndicationsforResection. Intheabsenceofrandomized
controlled data to guide treatment recommendations, the
Sendai International Consensus Guidelines [21, 55], ﬁrst
published online in 2005 by the International AssociationDiagnostic and Therapeutic Endoscopy 7
of Pancreatology, identiﬁed several factors as relative indica-
tions for resection of IPMN. These include a main-duct
component, diameter >3cm, any solid component, and
the presence of symptoms attributable to the cyst, such
as abdominal pain, weight loss, and pancreatitis (Table 2).
Rapidrateofgrowthofthecystandyoungage(suchthatlife-
long surveillance would be prohibitively burdensome for the
patient) may be considered relative indications outside the
Sendai Guidelines. Resection recommended as the mainstay
of treatment for lesions thought to have increased the
potential for harboring signiﬁcant dysplasia or an associated
invasivecarcinoma,andindeeditistheonlypotentiallycura-
tive option for such lesions.
Unlike a cystic lesion thought to be IPMN, which may
be observed or resected, depending on the above-mentioned
riskfactors,anylesionthoughttobeMCNshouldberesected
until data are available to better stratify these patients, if such
data ever exist.
Regarding the serous lesions SCN and SPN, all lesions
known to be SCN may be left in place and all those known to
be SPN should be resected. In reality, however, a given cystic
lesion of the pancreas is not generally known to be one or the
other with suﬃcient certainty, even despite all of the above-
discussed diagnostic modalities. Therefore, each pancreato-
logist and patient must together carefully weigh the risks and
beneﬁts of resection and surveillance on a case-by-case basis
(see Surveillance, below).
Thechiefdiﬃcultyis,ofcourse,thefactthattheonlyway
to achieve a deﬁnitive diagnosis in many cases of pancreatic
cysts is to remove the cyst and subject it to pathologic
evaluation. Although pancreatectomy is curative in most
cases of cystic lesions of the pancreas, it is associated with
a perioperative morbidity rate of 30–60% [56–58]a n da
mortality rate ranging from <1% to 2% [56–59]. In addition
to complications associated with any operation in general,
such as bleeding and infection, complications speciﬁc to
the resection of pancreatic lesions include pancreatic or
biliary ﬁstula, delayed gastric emptying, and pancreatic
insuﬃciency, both exocrine and endocrine.
5.2.2. Cyst Ablation. In an eﬀort to avoid a more inva-
sive treatment and the associated complications, pancreatic
cyst ablation has been suggested both as an experimental
approach to treatment for pancreatic cysts in general and for
treatment of those patients speciﬁcally deemed unﬁt or at a
too high risk for a major operation (Figure 1)[ 60].
Although less commonly employed than resection, pan-
creatic cyst ablation is an increasingly studied modality, typi-
callyusing EUS to guide injection of alcoholor other ablative
agents into the cyst cavity. Ethanol has the advantages of
being safe, inexpensive, readily available, and having the
potential to rapidly ablate the entire cyst wall epithelium.
A 2005 pilot study using escalating doses (5% to 80%) of
ethanol for 3- to 5-minute lavage [61] showed histological
evidence of epithelial ablation in resected cysts. Patients
reported no symptoms at 2 hours, 72 hours, and 6–12
months following the procedure, with no complications
detected [61], although theoretical complications include
acute pancreatitis, hemorrhage, intoxication, and abdominal
pain.
In an eﬀort to assess eﬀectiveness as well as to further
assess safety, DeWitt et al. [62] compared ethanol ablation
to saline lavage in a randomized controlled trial including
42 ethanol-lavaged and 17 saline-lavaged patients. Ethanol
lavage resulted in greater decrease in pancreatic cyst size
(−43%), compared with saline (−11%), with similar safety
proﬁle [62]. Four patients underwent resection after lavage
of mucinous cysts (2 who decided to drop out after lack of
response (one to saline and one to ethanol) and 2 whose cyst
ﬂuid had atypical cells), and histology of resected pancreata
showed IPMNs in 3 and MCN in 1 patient; not surprisingly,
there was more extensive ablation (50% to 100% of cyst
epithelium) in the ethanol group than the saline group (0%).
Resolution by CT imaging was seen in 33% (12 of 36 cysts
lavaged with saline alone [1], ethanol alone [4], saline then
ethanol [13], ethanol then ethanol [18]) [62].
Subsequent studies of EUS with ethanol ablation have
expanded the ﬁeld to include ablation of septated cysts
(successful) [63], the addition of paclitaxil to increase
ablative capacity of the lavage (62% of patients had complete
resolution) [64], and longer (2 years) followup of ablated
patients (no recurrence during second year) [65]. Although
these preliminary data suggested that ethanol ablation is
safe and feasible, prospective randomized trials with longer
followup in more patients comparing ablation with resection
are needed.
5.2.3. Surveillance. Patients too unﬁt to undergo resection or
whosecystsdonotmeettheabove-mentionedSendaicriteria
for treatment may undergo surveillance (Figure 1). Indeed,
not only a patient’s physiologic ﬁtness for resection but also
a patient’s goals must be considered. To this end, the Markov
modeling and nomograms have been used in a recent study
[66] to assist patients with small asymptomatic BD IPMNs
with decision making regarding the risks and beneﬁts of
resection versus surveillance. The decision to resect or to
surveil depended on the patient’s age and comorbidities, the
size of the cyst, and whether the patient values quality or
quantity of life more; that is, overall survival versus quality-
adjusted survival [66]: those valuing primarily survival,
irrespective of quality of life, would beneﬁt most from
resection of lesions >2cm. However, for patients valuing
quality of life over longevity, a 3-cm threshold for resection
w o u l db em o r ea p p r o p r i a t e .
6. Summary
The diagnosis and management of cystic lesions of the
pancreas is challenging and continues to evolve. The ﬁve
most common diagnoses are pseudocysts, SCN, SPN, MCN,
and IPMN. Pseudocysts are generally distinguishable based
on historical, clinical, and radiographic characteristics, leav-
ing the most important diﬀerentiation being between the
mucin-producing (often malignant or premalignant), MCN
and IPMN, and the serous (generally benign), SCN and
SPN, cysts. EUS and FNA with cyst-ﬂuid analysis have an8 Diagnostic and Therapeutic Endoscopy
increasingly important role in diagnosis. Among mucinous
lesions, those that require treatment (resection currently)
are any MCN, any MD IPMN, and BD IPMN larger than
3cm,symptomatic,orwithanassociatedmass.Inthefuture,
ethanol ablation may well supplant resection or at least
provide an alternative treatment in selected patients.
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